Novavax, Inc. (NVAX)
| Market Cap | 8.01B |
| Revenue (ttm) | 204.76M |
| Net Income (ttm) | -272.53M |
| Shares Out | 61.55M |
| EPS (ttm) | -5.66 |
| PE Ratio | n/a |
| Forward PE | 7.49 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $122.40 |
| Previous Close | $125.05 |
| Change ($) | -2.65 |
| Change (%) | -2.12% |
| Day's Open | 125.72 |
| Day's Range | 122.12 - 129.80 |
| Day's Volume | 2,466,113 |
| 52-Week Range | 6.31 - 178.51 |
This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors t...
Take a look at a few trending biotech stocks and decide if this is something you want to invest in.
Last year's stock market star is getting ready for its big moment -- or, has it already happened?
These companies' vaccines could bring in billions of dollars in revenue.
After a monster 2020 rally, NVAX stock has been quiet so far in 2021. But with good news building, this year too should be a strong one.
These are the small cap stocks with the best value, fastest growth, and most momentum for February 2021.
The NVAX stock battle now is heating up between the support below and the resistance above ... and the bulls have the momentum.
Covid-19 pharma stocks like NVAX stock and BNTX stock are making headlines as Joe Biden promises to vaccinate 100 million Americans. The post Covid-19 Vaccine Roundup: 5 Pharma Stocks Making t...
Novavax has achieved considerable clinical success with its Covid-19 vaccine. However, NVAX stock is too expensive.
Add these dirt cheap stocks to your portfolio while you still can.
These stocks could be set for big gains in 2021 even after huge returns last year.
This small biotech could be like the tortoise in Aesop's famous fable.
Each has more to offer than just a COVID-19 vaccine.
In the latest trading session, Novavax (NVAX) closed at $127.43, marking a -1.96% move from the previous day.
Novavax, Inc. (NASDAQ: NVAX) is beefing up its executive team as it prepares to release results of its late-stage coronavirus vaccine study and file for emergency use authorization. What Happe...
Novavax is making a play for a coronavirus vaccine, vs. giants like Pfizer, and other rivals like Moderna.
While comparing stocks, if other factors are similar, investors can look out for the one with higher earnings yield. Stocks including GM, WGO, NVAX and MT score high in that parameter.
GAITHERSBURG, Md., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
The next few weeks could be critical for the biotech's coronavirus vaccine prospects.
Both of these biotechs could be big winners in the COVID-19 vaccine market.
NVAX stock is poised for returns once its Phase 3 trial results come out, but potential investors should keep their eyes on the news. The post Novavax Will Likely Do Well Once Its Covid-19 Vac...
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
Vaccine developer Novavax (NASDAQ: NVAX) is seen as a key player in the Coronavirus vaccine space. Here's a quick overview of what has been happening with the company over the last few weeks.
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.
Investors seem perturbed by some reporting about top managers' recent financial moves.
Novavax lost the race to be first with a Covid-19 vaccine, but NVX-CoV2373 is nearing approval. It will boost NVAX stock in 2021.
Phase 3 trial delays are pushing NVAX stock down, but the biotech still has a reliable vaccine candidate expected to generate $3.9 billion. The post NVAX Stock Is Worth a Small Position but Va...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter BioPharma Solutions announced an agreement with Novavax to provide sterile manufacturing services for its COVID-19 vaccine candidate.
Top executives at U.S. pharmaceutical company Novavax Inc aren't waiting to see how well their COVID-19 vaccine works before they reap the financial rewards.
One big biotech and two small biotechs that share a common denominator: Great growth prospects.
Novavax, Inc. (NASDAQ: NVAX) shares are higher Friday following a coronavirus vaccine supply deal the company announced with the Australian government. Deal Sealed: Novavax, based in Gaithersb...
The three securities listed below could be of interest to investors, as their forward price-earnings ratios are lower than the S&P 500's historical average of 15. The projections of future ear...
As Covid-19 vaccine leaders took the headlines, NVAX stock slipped into the shadows. However, the former group's setbacks could spell upside opportunity for the latter.
GAITHERSBURG, Md., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Biotech, bitcoin, and renewable energy led the way.
NVAX traded down in December, but there wasn't really any bad news from the company. NVAX did produce some good news with a US/Mexico trial of the company's COVID-19 vaccine getting underway.
It trounced bitcoin in 2020 and has clear potential catalysts on the way.
Novavax (NASDAQ: NVAX) saw its stock gain over 3,000% last year. But it could have even more room to run as the market will get only crazier for vaccines this year.
The re-opening narrative is dominating activity in the market and governs decisions being made in the business economy, and with good reason. Perhaps never before has so much value been tied t...
GAITHERSBURG, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Vaccine specialist Novavax - which is seen as a key player in the Covid-19 vaccine space - saw its stock price decline by about 20% over December. Here are a few possible reasons for the decline.
Investors will soon have data to judge management's big projections.
About NVAX
Novavax, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead ad... [Read more...]
| Industry Biotechnology | IPO Date Dec 5, 1995 |
| CEO Stanley Erck | Employees 522 |
| Stock Exchange NASDAQ | Ticker Symbol NVAX |
Financial Performance
In 2019, Novavax's revenue was $18.66 million, a decrease of -45.57% compared to the previous year's $34.29 million. Losses were -$132.69 million, -28.18% less than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for Novavax stock is "Buy." The 12-month stock price forecast is 188.50, which is an increase of 54.00% from the latest price.